EKSO vs DBVT

Analysts rate Ekso Bionics Holdings, Inc.

(EKSO) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, DBV Technologies S.

A. (DBVT) delivered a total return of -69. 1%, compared to -85. 5% for Ekso Bionics Holdings, Inc. (EKSO). Over 10 years, the gap is even starker: DBVT returned -87. 0% versus EKSO's -99. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), DBV Technologies S.

A. (DBVT) is the lower-risk stock at 1. 26β versus Ekso Bionics Holdings, Inc. 's 2. 02β — meaning EKSO is approximately 61% more volatile than DBVT relative to the S&P 500. On balance sheet safety, DBV Technologies S. A. (DBVT) carries a lower debt/equity ratio of 13% versus 29% for Ekso Bionics Holdings, Inc. — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: DBV Technologies S.

A. grew EPS -347. 5% year-over-year, compared to -776. 8% for Ekso Bionics Holdings, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

DBV Technologies S.

A. (DBVT) is the more profitable company, earning 0. 0% net margin versus -91. 4% for Ekso Bionics Holdings, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DBVT leads at 0. 0% versus -104. 1% for EKSO. At the gross margin level — before operating expenses — EKSO leads at 53. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, EKSO (0.

8% yield) pays a dividend. DBVT does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, DBV Technologies S.

A. (DBVT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 26)). Ekso Bionics Holdings, Inc. (EKSO) carries a higher beta of 2. 02 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (DBVT: -87. 0%, EKSO: -99. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

EKSO pays a dividend while DBVT does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.